AGF Investments Inc. lessened its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,001,664 shares of the company’s stock after selling 72,891 shares during the quarter. AGF Investments Inc.’s holdings in Teva Pharmaceutical Industries were worth $18,982,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Schroder Investment Management Group increased its stake in shares of Teva Pharmaceutical Industries by 22.7% during the 3rd quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after purchasing an additional 1,147,683 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 4.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock worth $106,271,000 after purchasing an additional 259,891 shares during the last quarter. State Street Corp increased its stake in shares of Teva Pharmaceutical Industries by 5.1% during the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock worth $158,254,000 after purchasing an additional 232,924 shares during the last quarter. Macquarie Group Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 350.3% during the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after purchasing an additional 3,429,448 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Teva Pharmaceutical Industries by 0.9% during the 4th quarter. Swiss National Bank now owns 3,523,499 shares of the company’s stock worth $66,770,000 after purchasing an additional 32,000 shares during the last quarter. Hedge funds and other institutional investors own 51.93% of the company’s stock.

Shares of Teva Pharmaceutical Industries Ltd (NYSE TEVA) opened at $18.52 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Ltd has a 1-year low of $10.85 and a 1-year high of $37.94. The firm has a market cap of $18,430.00, a price-to-earnings ratio of -1.14, a price-to-earnings-growth ratio of 1.37 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The firm had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the firm earned $1.38 EPS. The business’s revenue was down 15.9% on a year-over-year basis. equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.73 earnings per share for the current year.

Several research analysts have recently commented on the stock. Wells Fargo & Co restated a “sell” rating on shares of Teva Pharmaceutical Industries in a research note on Tuesday. Credit Suisse Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $20.00 to $23.00 in a research note on Sunday. ValuEngine lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a research note on Friday, February 9th. Finally, Leerink Swann dropped their price target on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a research note on Friday, February 9th. Ten equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and a consensus target price of $21.26.

ILLEGAL ACTIVITY NOTICE: “AGF Investments Inc. Reduces Holdings in Teva Pharmaceutical Industries Ltd (TEVA)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/14/agf-investments-inc-reduces-holdings-in-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.